115 related articles for article (PubMed ID: 12054761)
1. Domain-swapped structure of a mutant of cyanovirin-N.
Botos I; Mori T; Cartner LK; Boyd MR; Wlodawer A
Biochem Biophys Res Commun; 2002 May; 294(1):184-90. PubMed ID: 12054761
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library.
Han Z; Xiong C; Mori T; Boyd MR
Biochem Biophys Res Commun; 2002 Apr; 292(4):1036-43. PubMed ID: 11944919
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping.
Yang F; Bewley CA; Louis JM; Gustafson KR; Boyd MR; Gronenborn AM; Clore GM; Wlodawer A
J Mol Biol; 1999 May; 288(3):403-12. PubMed ID: 10329150
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants.
Chang LC; Bewley CA
J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763
[TBL] [Abstract][Full Text] [Related]
5. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
[TBL] [Abstract][Full Text] [Related]
6. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
[TBL] [Abstract][Full Text] [Related]
7. Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity.
Barrientos LG; Lasala F; Delgado R; Sanchez A; Gronenborn AM
Structure; 2004 Oct; 12(10):1799-807. PubMed ID: 15458629
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
[TBL] [Abstract][Full Text] [Related]
9. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of cyanovirin-N, a potent HIV-inactivating protein.
Bewley CA; Gustafson KR; Boyd MR; Covell DG; Bax A; Clore GM; Gronenborn AM
Nat Struct Biol; 1998 Jul; 5(7):571-8. PubMed ID: 9665171
[TBL] [Abstract][Full Text] [Related]
11. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium.
Mori T; Gustafson KR; Pannell LK; Shoemaker RH; Wu L; McMahon JB; Boyd MR
Protein Expr Purif; 1998 Mar; 12(2):151-8. PubMed ID: 9518455
[TBL] [Abstract][Full Text] [Related]
12. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
Colleluori DM; Tien D; Kang F; Pagliei T; Kuss R; McCormick T; Watson K; McFadden K; Chaiken I; Buckheit RW; Romano JW
Protein Expr Purif; 2005 Feb; 39(2):229-36. PubMed ID: 15642474
[TBL] [Abstract][Full Text] [Related]
13. Role of the amino acid sequence in domain swapping of the B1 domain of protein G.
Sirota FL; Héry-Huynh S; Maurer-Stroh S; Wodak SJ
Proteins; 2008 Jul; 72(1):88-104. PubMed ID: 18186476
[TBL] [Abstract][Full Text] [Related]
14. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
[TBL] [Abstract][Full Text] [Related]
15. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
[TBL] [Abstract][Full Text] [Related]
16. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions.
McFadden K; Cocklin S; Gopi H; Baxter S; Ajith S; Mahmood N; Shattock R; Chaiken I
Proteins; 2007 May; 67(3):617-29. PubMed ID: 17348010
[TBL] [Abstract][Full Text] [Related]
17. A new mutant of bovine seminal ribonuclease with a reversed swapping propensity.
Ercole C; Spadaccini R; Alfano C; Tancredi T; Picone D
Biochemistry; 2007 Feb; 46(8):2227-32. PubMed ID: 17269658
[TBL] [Abstract][Full Text] [Related]
18. The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped non-covalent form of the enzyme.
Merlino A; Ercole C; Picone D; Pizzo E; Mazzarella L; Sica F
J Mol Biol; 2008 Feb; 376(2):427-37. PubMed ID: 18164315
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamic effects of proline introduction on protein stability.
Prajapati RS; Das M; Sreeramulu S; Sirajuddin M; Srinivasan S; Krishnamurthy V; Ranjani R; Ramakrishnan C; Varadarajan R
Proteins; 2007 Feb; 66(2):480-91. PubMed ID: 17034035
[TBL] [Abstract][Full Text] [Related]
20. Atomic mapping of the interactions between the antiviral agent cyanovirin-N and oligomannosides by saturation-transfer difference NMR.
Sandström C; Berteau O; Gemma E; Oscarson S; Kenne L; Gronenborn AM
Biochemistry; 2004 Nov; 43(44):13926-31. PubMed ID: 15518540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
